The mission of Oxygen Biotherapeutics is to research, develop and market oxygen related topical and intravenous products based on our perfluorocarbon technology.
Currently, we have one product candidate, Oxycyte PFC emulsion, in Phase IIb clinical trials in Switzerland and Israel for use in treating traumatic brain injury (TBI).
Products & Indications
Traumatic Brain Injury
Oxygen Biotherapeutics Names Col. Charles L. Pamplin III, M.D., Chief Medical Officer - Expertise in the development of numerous commercialized drugs and his military background to support Company’s development path -
MORRISVILLE, N.C.--(BUSINESS WIRE)--May. 21, 2013-- Oxygen Biotherapeutics, Inc. (“OBI”) (NASDAQ: OXBT), today announced Col. (ret.) Charles L. Pamplin III, M.D., was appointed to the position of Chief Medical Officer effective May 20. In this position, he reports to the Chief Executive Officer. Dr. Pamplin will be implementing the Company’s strategic clinical development plan. His responsibilities will include overseeing Clinical Development of Oxycyte, OBI’s lead product candidate currently in Phase IIb clinical trials in Israel and Switzerland for traumatic brain injury, as well as preclinical studies here in the U.S. more..
About Oxygen Biotherapeutics
Oxygen Biotherapeutics is the tissue oxygenation company
Oxygen is essential to life. When that supply is shut off the results can range from minor to devastating. At Oxygen Biotherapeutics, our goal is to help the human body maintain a sufficient oxygen supply to stop disease and damage to tissues that occurs when the flow of oxygen is suddenly interrupted or diminished.
Currently, we are developing medical and cosmetic products designed to deliver oxygen to specific tissues in the body that are deprived of oxygen. Our most advanced product, Oxycyte PFC, is in Phase IIb clinical trials in Switzerland and Israel for the traumatic brain injury. Oxycyte PFC is an intravenously delivered perfluorocarbon-based drug that we believe has therapeutic benefits for acute ischemic conditions. The first cohort of the Phase IIb trail is complete and efforts are being made to resume the trials later this fiscal year with planned expansions in other countries. more..